Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxymetazoline nasal spray and physical capacity in COPD
2024-520177-12-00Phase 3Authorised
- Sponsor
- Sørlandet sykehus
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of xylometazoline in chronic obstructive pulmonary disease (COPD), sponsored by Sørlandet sykehus. Primary endpoint: walking distance. Planned start Jan 2025; status: authorised.
02
Drugs
xylometazoline
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2024-520177-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520177-12-00.